Key Highlights
- Nutranomics, formerly known as Buka Ventures Inc., was an active filer of quarterly, annual, and current reports through the mid-2010s.
- The company later pursued capital-raising under Regulation A, with offering-related filings on record into 2022, its most recent notable disclosure.
- Since 2022, no substantive new reporting has appeared for the nutritional-supplement company.
- NNRX traded near $0.000001 with a market Capitalization in the low tens of thousands of dollars in the last closing session.
Nutranomics, Inc. (OTC:NNRX) is a name from the nutritional-supplement corner of the micro-cap market, and its ticker still surfaces on penny-stock screens even though the company's public reporting has fallen silent. Quoted at essentially a hundredth of a cent with a Market Value in the tens of thousands of dollars in the last closing session, NNRX is a study in how a small consumer-health venture can drift into dormancy.
Company and Latest Development
Nutranomics operated in the food-products and nutritional-supplement space, a Business it built through a reverse-merger path. SEC EDGAR shows the entity was formerly known as Buka Ventures Inc., incorporated in Nevada, with operating addresses that migrated over time from the Salt Lake City, Utah area toward Oregon, and a primary industry classification tied to food products.
The company was an active filer of quarterly reports, annual reports and current reports through the mid-2010s and later pursued capital-raising under Regulation A, with offering-related filings on record into 2022. Since that period, no substantive new reporting has appeared.
What Is Driving Attention Around NNRX?
No confirmed corporate catalyst explains recent interest in NNRX. At a quoted price near $0.000001, the shares occupy the deepest tier of the penny-stock market, where trades are thin and price data can be erratic.
The attention captured by screeners reflects the stock's ultra-low price and lingering ticker rather than any verified announcement.
Key Numbers and Company Position
The verifiable numbers are limited. Market data place NNRX around $0.000001 with a Market Capitalisation in the low tens of thousands of dollars and no analyst rating, figures consistent with a dormant shell but not independently confirmed.
Because Nutranomics has not filed current financial statements in recent years, there is no up-to-date, audited view of revenue, cash, or obligations.
What Could Come Next?
For a quiet, non-reporting nano-cap, the plausible developments are structural: a resumption of SEC or OTC reporting, a change in control, a reverse merger, or a renewed Capital raise. None is confirmed for Nutranomics.
Any real progress would most likely be signalled through a fresh EDGAR filing or an OTC Markets update.
Risks to Watch
NNRX carries the full slate of deep-penny risks: negligible liquidity, opaque financials, wide spreads, and a high likelihood of total loss. Sub-penny consumer-health shells are also common vehicles for promotional activity, so unverified news should be treated with caution.
Without current disclosure, there is no reliable basis to value the equity, and dilution or dormancy remain live possibilities.
A Supplement Brand That Stopped Reporting
Nutranomics, Inc. reads today less like an operating supplement brand and more like a dormant, ultra-low-priced ticker with a paper trail that thins out after 2022. The verifiable anchors, its former life as Buka Ventures, its Nevada incorporation, and its Regulation A offering history, are backward-looking.
The practical watch-items are simple: whether Nutranomics resumes reporting and whether any change-of-control or financing filing appears. Until then, NNRX remains a quiet, high-risk shell rather than a live growth story.



_11_19_2026_18_10_09_455845.jpg)

_11_19_2026_18_15_38_890267.jpg)
Please wait processing your request...